Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31558350 | 0.88 | LTB4R (0.53) | HTR6SIGMAR1BLMTSHRLTB4R | |
| SCHEMBL7241734 | 0.85 | HTR6 (0.46) | HTR6BLMTSHRLTB4RLTB4R2 | |
| SCHEMBL7244280 | 0.85 | HTR6 (0.46) | HTR6BLMTSHRLTB4RLTB4R2 | |
| SCHEMBL7250161 | 0.85 | OPRD1 (0.43) | HTR6SIGMAR1BLMTSHR | |
| SCHEMBL7243291 | 0.82 | ALDH1A1 (0.49) | HTR6SIGMAR1LTB4RLTB4R2ALDH1A1 | |
| SCHEMBL7245434 | 0.79 | BLM (0.44) | BLMTSHRALDH1A1 | |
| SCHEMBL7246265 | 0.76 | LTB4R (0.43) | BLMTSHRLTB4RLTB4R2 | |
| SCHEMBL7249674 | 0.76 | BLM (0.41) | BLMTSHRLTB4RLTB4R2ALDH1A1 | |
| SCHEMBL7241908 | 0.76 | CYP3A4 (0.50) | TSHRLTB4RLTB4R2ALDH1A1LMNA | |
| SCHEMBL7241767 | 0.76 | GRIN2B (0.47) | HTR6SIGMAR1PRCPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | HTR6 4496/4885SIGMAR1 2522/4885BLM 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.